ADASUVE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Adasuve, and what generic alternatives are available?
Adasuve is a drug marketed by Alexza Pharms and is included in one NDA. There are seven patents protecting this drug.
This drug has two hundred and twenty-seven patent family members in twenty-one countries.
The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this compound. Additional details are available on the loxapine profile page.
DrugPatentWatch® Generic Entry Outlook for Adasuve
There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for ADASUVE
| International Patents: | 227 |
| US Patents: | 7 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 40 |
| Clinical Trials: | 13 |
| Patent Applications: | 5,101 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ADASUVE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ADASUVE |
| What excipients (inactive ingredients) are in ADASUVE? | ADASUVE excipients list |
| DailyMed Link: | ADASUVE at DailyMed |
Recent Clinical Trials for ADASUVE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Lee's Pharmaceutical Limited | Phase 3 |
| University of Arkansas | Phase 4 |
| Mount Sinai Hospital, Chicago | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for ADASUVE
US Patents and Regulatory Information for ADASUVE
ADASUVE is protected by seven US patents.
Patents protecting ADASUVE
Delivery of antipsychotics through an inhalation route
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Method and apparatus for vaporizing a compound
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Method of forming an aerosol for inhalation delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Method of forming an aerosol for inhalation delivery
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Self-contained heating unit and drug-supply unit employing same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Self-contained heating unit and drug-supply unit employing same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Self-contained heating unit and drug-supply unit employing same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ADASUVE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | See Plans and Pricing | See Plans and Pricing |
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | See Plans and Pricing | See Plans and Pricing |
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | See Plans and Pricing | See Plans and Pricing |
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | See Plans and Pricing | See Plans and Pricing |
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | See Plans and Pricing | See Plans and Pricing |
| Alexza Pharms | ADASUVE | loxapine | POWDER;INHALATION | 022549-001 | Dec 21, 2012 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ADASUVE
See the table below for patents covering ADASUVE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2002311923 | See Plans and Pricing | |
| Hungary | 0401008 | AN AEROSOL FORMING DEVICE FOR USE IN INHALATION THERAPY | See Plans and Pricing |
| China | 101623528 | Method and apparatus for vaporizing a compound | See Plans and Pricing |
| Hong Kong | 1129077 | 用於汽化化合物的方法 (METHOD FOR VAPORIZING A COMPOUND) | See Plans and Pricing |
| Germany | 60239604 | See Plans and Pricing | |
| Japan | 2005525178 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ADASUVE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1389098 | CR 2013 00046 | Denmark | See Plans and Pricing | PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220 |
| 1389098 | C01389098/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: LOXAPINUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65461 13.12.2016 |
| 1389098 | 2013C/054 | Belgium | See Plans and Pricing | PRODUCT NAME: LOXAPINE; AUTHORISATION NUMBER AND DATE: EU/1/13/823/001 20130225 |
| 1389098 | CA 2013 00046 | Denmark | See Plans and Pricing | PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220 |
| 1389098 | SPC/GB13/055 | United Kingdom | See Plans and Pricing | PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220 |
| 1389098 | 300609 | Netherlands | See Plans and Pricing | PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
